Truveris

12/10/2022

Need to pick up a few CEU credits? Join Truveris and Mployer Advisor for our "Pharmacy Benefits 101" webinar on October 19th. We'll dig into the prescription drug landscape, PBM contracting strategies, and ways to control costs. Save your seat here: https://hubs.ly/Q01pfT670

11/10/2022

The gross to net "bubble" continues to inflate, making it harder for life sciences brands to grow their market share. But with three innovative patient access strategies, there's still a clear path forward to a dynamic patient access program. https://hubs.ly/Q01p7Nzw0

The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?

10/10/2022

Attention brokers and plan sponsors! Truveris and Mployer Advisor are teaming up to offer an expert panel on "pharmacy benefits 101" this October 19th. Will we see you there? Seats are filling up fast: https://hubs.ly/Q01pfT630

09/10/2022

Transparency is a big buzzword in pharmacy right now, but not everyone has the same definition. Here's how we define transparency. Watch the full recording of our webinar on transparency in the pharmacy ecosystem below. https://hubs.ly/Q01p7K_G0

Watch on-demand this Truveris Webinar, "Transparency in Pharmacy: Innovative Strategies to Drive Outcomes for Self-Funded Plans."

07/10/2022

Truveris helps brands maximize patient access when their drug is included in copay accumulators and maximizer programs. Read our guide on indicators that your drug will be included in one of these cost-containment programs.

How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.

06/10/2022

Please join us in welcoming two new hires: Ayoub and Ryan! We're thrilled that you've joined us on our mission to make prescription drugs more accessible and affordable for those who need them. Welcome, Ayoub and Ryan 😀

Are you interested in working at an award-winning healthtech company? Join us: https://hubs.ly/Q01nWw1W0

05/10/2022

Employers are planning for another year of increased healthcare spending in 2023. SHRM reports that about two-thirds of employers surveyed agree that transparent pricing and a curb to OOP drug expenses are critical to containing healthcare costs. https://hubs.ly/Q01mCvkT0

The rise in costs for 2023 group health plans is forecast to be significantly higher than the increase for 2022 but to still lag overall inflation. Increasing access to quality providers and making prices more transparent are top employer goals.

04/10/2022

Many companies are struggling with expensive pharmacy benefits costs and are turning to copay assistance programs to control costs. Learn more about how these programs are structured.

Plan sponsors are increasingly turning to copay assistance strategies to lower the cost of specialty drugs. What should they know?

02/10/2022

The 340B program reached a record-high number of purchases in 2021, coming in at $43.9 billion in spend. That's $5.9 billion more in spend compared to the year prior. Read Drug Channels's recent report to learn more about 340B.

30/09/2022

If your plan is self-funded, you should have a strategy for containing the costs of specialty drugs. Learn more here: https://hubs.ly/Q01kL3JS0

As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?

29/09/2022

Per , in 2021, 80% of patients with commercial insurance belonged to a plan that offered copay accumulators. What does this mean for pharma? Get up to speed on how your brand might be affected with our exclusive guide.

How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.

29/09/2022

How will need to adjust now that the IRA has passed? And how will this law affect other categories of drugs, like biosimilars and vaccines? Read this guide from the life sciences team at Epstein Becker & Green to learn more.
https://hubs.ly/Q01mCqnD0

This Insight analyzes key pharmaceutical drug cost and drug pricing provisions in the IRA and highlights what actors in the pharmaceutical chain continuum should pay attention to as the law is implemented.

28/09/2022

Biopharma companies have to fight for their spots in a competitive marketplace, which means they have to get creative with their strategies and investments. These four innovative techniques can help to ensure investment success and a strong competitive edge.

Biopharma companies’ pipelines are full of assets they source externally to access innovation. Four practices will help ensure their investments flourish at a time of fierce competition.

27/09/2022

Our team just keeps growing! 📈 Please help us offer a very warm welcome to three new Truverians: Kyra, Benjamin, and Kimberly! We are thrilled to have this dynamic trio onboard. 🎉

Learn more about how Truverians like Kyra, Benjamin, and Kimberly are working to transform the pharmacy ecosystem: https://hubs.ly/Q01mc1Ct0

26/09/2022

If you weren't able to join our roundtable this summer, don't worry! You can access the full recording on our Resource Center. Tune in to hear from HR industry leaders about how they're planning to address the foremost pharmacy benefits concerns facing HR professionals today.

Watch Truveris' exclusive HR round table discussion with HR leaders from enterprise-level organizations, originally recorded on June 8, 2022.

25/09/2022

Pharmacists are the final connection between the patient and the medication they need. Without them, the pharmacy ecosystem would not function in the way we all depend upon. Happy World Pharmacist's Day to the pharmacists at Truveris - and to those across the globe 💊👏

24/09/2022

As technology from the biotech space becomes more advanced, the way we formulate and administer medicine is changing. Take a look at these investment trends in the biotech space to see where the industry may be going next.

McKinsey research shows from 2019 to 2021, VCs plowed $35 billion into biotechs with advanced platform technologies that could transform the industry

23/09/2022

Is your drug approaching launch? If so, you should scenario plan for if it is included in an accumulator or maximizer program. Start by taking our quick quiz to see how likely it is that your brand is included in one of these programs. https://hubs.ly/Q01mNh850